La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Adial Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Adial Pharmaceuticals..

Adial Pharmaceuticals (NASDAQ:ADIL) Azioni, Catena delle Opzioni

Adial Pharmaceuticals

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals Inc

Baird analyst David Tarantino maintains Dutch Bros (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) with a Outperform and lowers the price target from $80 to $66.

News

Price Target

Analyst Ratings

BROS

Baird Maintains Outperform on Dutch Bros, Lowers Price Target to $66

Gilat Satellite Networks Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILT#NASDAQ">GILT</a>) announced on Monday that it has <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44663247/gilat-awarded-up-to-23-million-multi-year-contract-to-service-satellite-transportable-terminal-uni" rel="noreferrer noopener">secured a contract</a> to deliver ongoing sustainment and support services for Satellite Transportable Terminal (STT) units deployed globally in support of U.S. Department of Defense (DoD) operations.
The agreement includes a base term with optional extensions of up to five years, bringing the total potential contract value to $23 million.
Under the terms of the deal, Gilat Defense will provide critical program management, field services, and technical support to ensure the operational readiness and long-term reliability of these vital communication systems.
"This contract reinforces the ongoing critical role our SATCOM systems play in supporting the U.S. DoD's global operations. We remain committed to delivering superior performance and service to our trusted defense partners worldwide," said Nicole Robinson, President of Gilat DataPath.
The announcement follows a $6 million <a href="https://www.benzinga.com/pressreleases/25/03/g44137836/gilat-receives-6-million-defense-contract-to-provide-military-communications-solutions-in-asia-pac" target="_blank" rel="noreferrer noopener">order</a> last month, in which Gilat's Defense Division was selected to supply an Asian-Pacific military organization with its advanced SkyEdge II-c platform. The system will support secure communications across fixed and mobile defense sites and feature enhanced air interface cybersecurity.
Price Action: At the last check on Monday, Gilat shares were trading higher by 4.35% at $5.76 premarket.

Contracts

GILT

Gilat Wins Defense Support Deal Worth Up To $23 Million For Global SATCOM Services

Baird analyst David George upgrades KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>) from Neutral to Outperform and maintains the price target from $18 to $18.

Upgrades

Baird Upgrades KeyCorp to Outperform, Maintains Price Target to $18

UBS analyst Joshua Spector upgrades Sealed Air (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEE#NYSE">SEE</a>) from Neutral to Buy and maintains the price target from $38 to $38.

UBS Upgrades Sealed Air to Buy, Maintains Price Target to $38

Earnings

HTLM

Homestolife FY 2024 GAAP EPS $(0.11) Down From $0.02 YoY, Sales $4.173M Down From $5.072M YoY

Collaboration Seeks to Enhance Ukraine's Mine Action Capabilities with Safe Pro's Cutting-Edge Patented AI Technology
Safe Pro Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPAI#NASDAQ">SPAI</a>) ("Safe Pro" or the "Company"), a leader in artificial intelligence (AI)-powered defense and security solutions, has entered into a multi-year Memorandum of Understanding (MOU) with Ukraine's Center of Excellence for Mine Action and Environmental Security (the "Center of Excellence" or "the Center"). Together, they will exam ways to integrate Safe Pro's patented AI-powered image processing technology, SpotlightAI&#x2122;, into Ukraine's demining methodologies and training programs to modernize the nation's approach to landmine detection and clearance.

SPAI

Safe Pro Group Enters Multi-Year MOU With Ukraine's Center Of Excellence For Mine Action To Integrate SpotlightAI Into Ukraine's Demining Methodologies And Training Programs To Enhance Landmine Detection And Clearance

Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) will release earnings results for the second quarter, before the <a href="https://www.benzinga.com/quote/WBA/earnings">opening bell on Tuesday, April 8.</a>
Analysts expect the company to report quarterly earnings at 53 cents per share, down from $1.2 per share in the year-ago period. According to data from Benzinga Pro, Walgreens projects quarterly revenue at $38.0 billion, compared to $37.05 billion a year earlier.
On March 6, Walgreens Boots Alliance entered an agreement to be acquired by private equity firm Sycamore Partners.
With the recent buzz around Walgreens, some investors may also be eyeing potential gains from the company's dividends. As of now, Walgreens offers an annual dividend yield of 9.36%, which is a quarterly dividend amount of 25 cents per share ($1.00 a year).  
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $64,080 or around 6,000 shares. For a more modest $100 per month or $1,200 per year, you would need $12,816 or around 1,200 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($1.00 in this case). So, $6,000 / $1.00 = 6,000 ($500 per month), and $1,200 / $1.00 = 1,200 shares ($100 per month).
Note that dividend yield can change on a rolling basis as the dividend payment and stock price fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
WBA Price Action: Shares of Walgreens fell 3.4% to close at $10.68 on Friday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44645517/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-4-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Markets

Trading Ideas

How To Earn $500 A Month From Walgreens Stock Ahead Of Q2 Earnings

UBS analyst Joshua Spector downgrades LyondellBasell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) from Neutral to Sell and lowers the price target from $76 to $51.

Downgrades

UBS Downgrades LyondellBasell Industries to Sell, Lowers Price Target to $51

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/04/04/final-trades-jpmorgan-amazon-rh-and-the-2-year-treasury.html">Halftime Report Final Trades</a>,&#8221; Jason Snipe of Odyssey Capital Advisors said Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) is 30% off the 52-week high level.
Adding support to his choice, WestPark Capital analyst Curtis Shauger, on April 1, initiated coverage on Amazon.com with a Buy rating and announced a price target of $280.
Stephen L. Weiss of Short Hills Capital Partners named U.S. 2 Year Treasury as <a href="https://www.benzinga.com/topic/treasury-yields">his final trade</a>.
Jim Lebenthal of Cerity Partners picked JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) ahead of first-quarter earnings.
JPMorgan will host a conference call to review first-quarter financial results on Friday, April 11. Analysts expect the bank to report quarterly earnings at $4.65 per share, up from $4.44 per share in the year-ago period. JPMorgan projects quarterly revenue of $44.05 billion, compared to $41.93 billion a year earlier.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Bryn Talkington of Requisite Capital Management said RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) is another name she likes in her Vietnam basket.
On the earnings front, RH, on April 2, reported fourth-quarter revenue of $812.41 million, missing the consensus estimate of $829.56 million, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. The luxury retailer reported fourth-quarter adjusted earnings of $1.58 per share, missing analyst estimates of $1.92 per share.
Price Action:
<ul>
<li>JPMorgan shares dipped 7.5% to close at $210.28 on Friday.</li>
<li>Amazon shares fell 4.2% to close at $171.00 during Friday's session.</li>
<li>RH shares declined 2.5% to settle at $145.66 on Friday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44645517/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-4-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields</a></li>
</ul>
Image: Shutterstock

Media

AMZN

Amazon, JPMorgan, RH And More: CNBC's 'Final Trades'

Baird analyst David George upgrades First Horizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) from Neutral to Outperform and maintains the price target from $22 to $22.

Baird Upgrades First Horizon to Outperform, Maintains Price Target to $22

UBS analyst Joshua Spector upgrades Axalta Coating Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>) from Neutral to Buy and lowers the price target from $42 to $40.

AXTA

UBS Upgrades Axalta Coating Systems to Buy, Lowers Price Target to $40

Baird analyst David George upgrades Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>) from Neutral to Outperform and maintains the price target from $47 to $47.

FITB

Baird Upgrades Fifth Third Bancorp to Outperform, Maintains Price Target to $47

NMAX

Newsmax Enters Standby Equity Purchase Agreement For Up To $1.2B With Yorkville Advisors

The Company's flagship patented nicotinamide riboside (NR) ingredient, Niagen&#xAE;, is manufactured, encapsulated, and bottled in the U.S. and is currently classified as exempt from tariffs, minimizing exposure to tariff-related risks

NAGE

Niagen Bioscience Confirms Its Operations Of Niagen Currently Classified As Exempt From Tariffs

<ul>
<li>Conduit expands its partnership with Sarborg to apply advanced machine learning-driven analysis on clinical data from its AstraZeneca-acquired assets, aiming to uncover new insights and optimize development pathways. &nbsp;</li>
</ul>
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announces that it has entered into an additional license and use agreement (the "Additional Agreement") with&nbsp;Sarborg Limited&nbsp;("Sarborg") to expand the scope of work on Conduit's acquired AstraZeneca assets, including&nbsp;AZD1656, AZD5658, and AZD5904.
Under the agreement,&nbsp;Sarborg&nbsp;will apply its proprietary&nbsp;machine learning algorithms&nbsp;to conduct an in-depth analysis of Conduit's clinical and safety data, with the goal of uncovering missed insights, identifying potential drug repurposing opportunities, and highlighting gaps in existing datasets. A key focus will be the re-evaluation of historical clinical trial data, including endpoints, to determine whether specific patient subgroups may have demonstrated therapeutic benefits, findings that could refine Conduit's future clinical development strategy.
Sarborg has granted Conduit a&nbsp;non-exclusive, non-transferable license&nbsp;to access its advanced algorithmic platform for the duration of the six-month agreement. The collaboration builds upon the existing&nbsp;Services Agreement&nbsp;between the two parties, which remains in full effect.

Biotech

General

Conduit Pharmaceuticals Expands Partnership With Sarborg To Apply Advanced Machine Learning Analysis On Clinical Data From AstraZeneca-Acquired Assets, Aiming To Uncover New Insights And Optimize Development Pathways For AZD1656, AZD5658, And AZD5904

Baird analyst David Tarantino downgrades Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) from Outperform to Neutral and lowers the price target from $114 to $85.

SBUX

Baird Downgrades Starbucks to Neutral, Lowers Price Target to $85

BNZI

Banzai Said It Has Paid Off ~$20.3M Of Outstanding Debt Obligations In Total Through Q1

HTCR

HeartCore Partners With NEC Solution Innovators To Enhance CMS Implementation Process

<a href="https://www.benzinga.com/topic/semiconductors">Semiconductors may power</a> everything from Tesla Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) cars to toothbrushes, but they can't outrun geopolitics.
With trade tensions heating up again, chip stocks have already taken a 25–30% hit, and JPMorgan analyst Harlan Sur says, &#8220;We see the potential for further ~10% downside (range of 5-15%) over the next six months.&#8221;
The good news? That may be the final flush before a rebound.
<h2 class="wp-block-heading">Tariffs Aren't The Problem &#8211; Demand Destruction Is</h2>
Despite investor jitters, Sur says the direct impact of tariffs on chipmakers is minimal. Most U.S.-designed chips are manufactured and tested abroad, not directly shipped into the U.S., shielding them from most tariff crossfire. Even China's retaliatory moves barely dent the sector directly.
Instead, the real problem lies in sticker shock. With end-products like smartphones and cars expected to rise 5–10% in price, consumers may start pulling back. A $300-more-expensive iPhone or a costlier EV could stall demand, ultimately hurting semiconductor sales.
Inventory caution from buyers only adds to the pressure.
Read Also: <a href="https://www.benzinga.com/25/04/44644871/nvidia-slips-into-bearish-trend-as-hsbc-downgrades-ai-giant">Nvidia Slips Into Bearish Trend As HSBC Downgrades AI Giant</a>
<h2 class="wp-block-heading">2018 Called &#8211; It Wants Its Trade War Back</h2>
Sur points to the 2018 U.S.-China tariff battle as a cautionary tale. Back then, chipmakers were riding high—until trade tensions slammed the brakes on the upcycle. Demand weakened, earnings were revised down and stocks nosedived by up to 35%. Memory stocks were hit the hardest, while software-centric names like Synopsys proved more defensive.
Sur sees echoes of that pattern in 2025: stocks are selling off ahead of earnings cuts, which could help clear the air for recovery. If history repeats, a three-to-five-month drawdown followed by a Fed-assisted rebound isn't out of the question.
<h2 class="wp-block-heading">Broadcom, Analog Devices, KLA, Synopsis: Selective Is The Safe Play</h2>
In this storm, Sur's sticking with what held up last time. He favors Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), Analog Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>), KLA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) and Synopsys Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) &#8211; stocks that blend strong fundamentals with exposure to AI, design software and increasing chip complexity.
These names outperformed during the 2018-2019 drawdown and are positioned to be more resilient this time around.
The bottom line? 
Semiconductor stocks may not be done falling, but with earnings resets coming soon, the worst might be behind us.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/global/25/04/44645946/microsoft-halts-data-center-expansions-due-to-semiconductor-tariff-concerns-ai-overcapacity-fears">Microsoft Halts Data Center Expansions Due To Semiconductor Tariff Concerns, AI Overcapacity Fears</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Tech

AVGO

KLAC

SNPS

TSLA

Broadcom, Analog Devices Could Slide ~10%, Analyst Warns, But A Bottom Could Be Near

Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) today announced the execution of long-term charter agreements, each inclusive of purchase options, for four vessels across its three brands.
The agreements are for: &nbsp;
<ul>
<li>Two Norwegian Cruise Line vessels, Norwegian Sky and Norwegian Sun, to be chartered to Cordelia Cruises, a premium cruise operator based in India. The charters are anticipated to begin in 2026 and 2027, respectively. &nbsp;</li>
<li>Seven Seas Navigator from Regent Seven Seas Cruises and Insignia from Oceania Cruises will be chartered to Crescent Seas, a residential cruise line. These charters are anticipated to begin in 2026 and 2027, respectively.</li>
</ul>

NCLH

Norwegian Cruise Line Holdings Announces Long-Term Charter Agreements For Four Vessels, Including Norwegian Sky And Norwegian Sun To Cordelia Cruises, And Seven Seas Navigator And Insignia To Crescent Seas, Set To Begin In 2026 And 2027

Press Releases

Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference

Management

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Health Care

Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Legal

Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Comments

Adial Pharmaceuticals

Adial Pharmaceuticals (ADIL) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO